课题基金 / 基金详情

A Canadian knowledge-to-action roadmap for evidence-informed implementation of first-tier clinical genome-wide sequencing for rare disease (K2A-RD)

A Canadian knowledge-to-action roadmap for evidence-informed implementation of first-tier clinical genome-wide sequencing for rare disease (K2A-RD)
加拿大知识到行动路线图,用于以证据为依据实施罕见疾病一级临床全基因组测序 (K2A-RD)
批准号:
495957
负责人:
Boycott Kym M
金额:
$100.14万
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2023
资助国家:
加拿大
项目状态:
未结题
起止时间:
2023-11-01 至 2026-11-01

项目摘要

项目成果

Boycott Kym M的其他基金

相似基金

相关文献

中文摘要
翻译
患有罕见疾病(RD)的加拿大人可能会花费数年时间试图得到诊断,咨询许多专家,忍受徒劳的测试。基因组测序是对一个人的DNA进行解码,寻找导致疾病的罕见突变,是诊断糖尿病的一种很好的测试方法
英文摘要
Canadians with rare disease (RD) can spend years trying to get a diagnosis, visiting many specialists and enduring futile testing. Genomic sequencing, which decodes a person's DNA looking for rare mutations that cause disease, is an excellent test for dia
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Care4Rare-SOLVE
Canada Research Chair - Tier 1
  • 批准号:
    404325
  • 项目类别:
  • 资助金额:
    $101.99万
  • 财政年份:
    2018
  • 负责人:
    Boycott Kym M
  • 依托单位:
Care4Rare Canada: Harnessing multi-omics to deliver innovative diagnostic care for rare genetic diseases in Canada (C4R-SOLVE)
Beyond the Exome: Decoding the Next Frontier of the Rare Disease Genome
海外基金